

Multi-Infarct Dementia Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/MAFA470C2838EN.html>

Date: March 2022

Pages: 68

Price: US\$ 3,250.00 (Single User License)

ID: MAFA470C2838EN

Abstracts

Multi-cerebral infarction dementia is a series of small strokes that cause disruption of blood flow to the brain. It is the highest incidence among people over 65 years of age.

This report contains market size and forecasts of Multi-Infarct Dementia in Global, including the following market information:

Global Multi-Infarct Dementia Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Multi-Infarct Dementia market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Pharmacological Treatment Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Multi-Infarct Dementia include Forest Laboratories, Janssen Pharmaceuticals, Novartis Pharmaceutical, Pfizer, Eisai, Ortho-McNeil Pharmaceutical, Takeda, Jubilant Cadista Pharmaceuticals and Takeda Pharmaceutical. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Multi-Infarct Dementia

companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Multi-Infarct Dementia Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Multi-Infarct Dementia Market Segment Percentages, by Type, 2021 (%)

Pharmacological Treatment

Non Pharmacological Treatment

Global Multi-Infarct Dementia Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Multi-Infarct Dementia Market Segment Percentages, by Application, 2021 (%)

Academic

Hospitals

Other

Global Multi-Infarct Dementia Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Multi-Infarct Dementia Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Multi-Infarct Dementia revenues in global market, 2017-2022
(estimated), (\$ millions)

Key companies Multi-Infarct Dementia revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Forest Laboratories

Janssen Pharmaceuticals

Novartis Pharmaceutical

Pfizer

Eisai

Ortho-McNeil Pharmaceutical

Takeda

Jubilant Cadista Pharmaceuticals

Takeda Pharmaceutical

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Multi-Infarct Dementia Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Multi-Infarct Dementia Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL MULTI-INFARCT DEMENTIA OVERALL MARKET SIZE

- 2.1 Global Multi-Infarct Dementia Market Size: 2021 VS 2028
- 2.2 Global Multi-Infarct Dementia Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Multi-Infarct Dementia Players in Global Market
- 3.2 Top Global Multi-Infarct Dementia Companies Ranked by Revenue
- 3.3 Global Multi-Infarct Dementia Revenue by Companies
- 3.4 Top 3 and Top 5 Multi-Infarct Dementia Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Multi-Infarct Dementia Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Multi-Infarct Dementia Players in Global Market
 - 3.6.1 List of Global Tier 1 Multi-Infarct Dementia Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Multi-Infarct Dementia Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

- 4.1.1 by Type - Global Multi-Infarct Dementia Market Size Markets, 2021 & 2028
- 4.1.2 Pharmacological Treatment
- 4.1.3 Non Pharmacological Treatment

4.2 By Type - Global Multi-Infarct Dementia Revenue & Forecasts

- 4.2.1 By Type - Global Multi-Infarct Dementia Revenue, 2017-2022
- 4.2.2 By Type - Global Multi-Infarct Dementia Revenue, 2023-2028
- 4.2.3 By Type - Global Multi-Infarct Dementia Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

- 5.1.1 By Application - Global Multi-Infarct Dementia Market Size, 2021 & 2028
- 5.1.2 Academic
- 5.1.3 Hospitals
- 5.1.4 Other

5.2 By Application - Global Multi-Infarct Dementia Revenue & Forecasts

- 5.2.1 By Application - Global Multi-Infarct Dementia Revenue, 2017-2022
- 5.2.2 By Application - Global Multi-Infarct Dementia Revenue, 2023-2028
- 5.2.3 By Application - Global Multi-Infarct Dementia Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Multi-Infarct Dementia Market Size, 2021 & 2028

6.2 By Region - Global Multi-Infarct Dementia Revenue & Forecasts

- 6.2.1 By Region - Global Multi-Infarct Dementia Revenue, 2017-2022
- 6.2.2 By Region - Global Multi-Infarct Dementia Revenue, 2023-2028
- 6.2.3 By Region - Global Multi-Infarct Dementia Revenue Market Share, 2017-2028

6.3 North America

- 6.3.1 By Country - North America Multi-Infarct Dementia Revenue, 2017-2028
- 6.3.2 US Multi-Infarct Dementia Market Size, 2017-2028
- 6.3.3 Canada Multi-Infarct Dementia Market Size, 2017-2028
- 6.3.4 Mexico Multi-Infarct Dementia Market Size, 2017-2028

6.4 Europe

- 6.4.1 By Country - Europe Multi-Infarct Dementia Revenue, 2017-2028
- 6.4.2 Germany Multi-Infarct Dementia Market Size, 2017-2028
- 6.4.3 France Multi-Infarct Dementia Market Size, 2017-2028
- 6.4.4 U.K. Multi-Infarct Dementia Market Size, 2017-2028

6.4.5 Italy Multi-Infarct Dementia Market Size, 2017-2028

6.4.6 Russia Multi-Infarct Dementia Market Size, 2017-2028

6.4.7 Nordic Countries Multi-Infarct Dementia Market Size, 2017-2028

6.4.8 Benelux Multi-Infarct Dementia Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Multi-Infarct Dementia Revenue, 2017-2028

6.5.2 China Multi-Infarct Dementia Market Size, 2017-2028

6.5.3 Japan Multi-Infarct Dementia Market Size, 2017-2028

6.5.4 South Korea Multi-Infarct Dementia Market Size, 2017-2028

6.5.5 Southeast Asia Multi-Infarct Dementia Market Size, 2017-2028

6.5.6 India Multi-Infarct Dementia Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Multi-Infarct Dementia Revenue, 2017-2028

6.6.2 Brazil Multi-Infarct Dementia Market Size, 2017-2028

6.6.3 Argentina Multi-Infarct Dementia Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Multi-Infarct Dementia Revenue, 2017-2028

6.7.2 Turkey Multi-Infarct Dementia Market Size, 2017-2028

6.7.3 Israel Multi-Infarct Dementia Market Size, 2017-2028

6.7.4 Saudi Arabia Multi-Infarct Dementia Market Size, 2017-2028

6.7.5 UAE Multi-Infarct Dementia Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Forest Laboratories

7.1.1 Forest Laboratories Corporate Summary

7.1.2 Forest Laboratories Business Overview

7.1.3 Forest Laboratories Multi-Infarct Dementia Major Product Offerings

7.1.4 Forest Laboratories Multi-Infarct Dementia Revenue in Global Market
(2017-2022)

7.1.5 Forest Laboratories Key News

7.2 Janssen Pharmaceuticals

7.2.1 Janssen Pharmaceuticals Corporate Summary

7.2.2 Janssen Pharmaceuticals Business Overview

7.2.3 Janssen Pharmaceuticals Multi-Infarct Dementia Major Product Offerings

7.2.4 Janssen Pharmaceuticals Multi-Infarct Dementia Revenue in Global Market
(2017-2022)

7.2.5 Janssen Pharmaceuticals Key News

7.3 Novartis Pharmaceutical

- 7.3.1 Novartis Pharmaceutical Corporate Summary
- 7.3.2 Novartis Pharmaceutical Business Overview
- 7.3.3 Novartis Pharmaceutical Multi-Infarct Dementia Major Product Offerings
- 7.3.4 Novartis Pharmaceutical Multi-Infarct Dementia Revenue in Global Market (2017-2022)
- 7.3.5 Novartis Pharmaceutical Key News
- 7.4 Pfizer
 - 7.4.1 Pfizer Corporate Summary
 - 7.4.2 Pfizer Business Overview
 - 7.4.3 Pfizer Multi-Infarct Dementia Major Product Offerings
 - 7.4.4 Pfizer Multi-Infarct Dementia Revenue in Global Market (2017-2022)
 - 7.4.5 Pfizer Key News
- 7.5 Eisai
 - 7.5.1 Eisai Corporate Summary
 - 7.5.2 Eisai Business Overview
 - 7.5.3 Eisai Multi-Infarct Dementia Major Product Offerings
 - 7.5.4 Eisai Multi-Infarct Dementia Revenue in Global Market (2017-2022)
 - 7.5.5 Eisai Key News
- 7.6 Ortho-McNeil Pharmaceutical
 - 7.6.1 Ortho-McNeil Pharmaceutical Corporate Summary
 - 7.6.2 Ortho-McNeil Pharmaceutical Business Overview
 - 7.6.3 Ortho-McNeil Pharmaceutical Multi-Infarct Dementia Major Product Offerings
 - 7.6.4 Ortho-McNeil Pharmaceutical Multi-Infarct Dementia Revenue in Global Market (2017-2022)
 - 7.6.5 Ortho-McNeil Pharmaceutical Key News
- 7.7 Takeda
 - 7.7.1 Takeda Corporate Summary
 - 7.7.2 Takeda Business Overview
 - 7.7.3 Takeda Multi-Infarct Dementia Major Product Offerings
 - 7.7.4 Takeda Multi-Infarct Dementia Revenue in Global Market (2017-2022)
 - 7.7.5 Takeda Key News
- 7.8 Jubilant Cadista Pharmaceuticals
 - 7.8.1 Jubilant Cadista Pharmaceuticals Corporate Summary
 - 7.8.2 Jubilant Cadista Pharmaceuticals Business Overview
 - 7.8.3 Jubilant Cadista Pharmaceuticals Multi-Infarct Dementia Major Product Offerings
 - 7.8.4 Jubilant Cadista Pharmaceuticals Multi-Infarct Dementia Revenue in Global Market (2017-2022)
 - 7.8.5 Jubilant Cadista Pharmaceuticals Key News
- 7.9 Takeda Pharmaceutical

- 7.9.1 Takeda Pharmaceutical Corporate Summary
- 7.9.2 Takeda Pharmaceutical Business Overview
- 7.9.3 Takeda Pharmaceutical Multi-Infarct Dementia Major Product Offerings
- 7.9.4 Takeda Pharmaceutical Multi-Infarct Dementia Revenue in Global Market (2017-2022)
- 7.9.5 Takeda Pharmaceutical Key News

8 CONCLUSION

9 APPENDIX

- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Multi-Infarct Dementia Market Opportunities & Trends in Global Market

Table 2. Multi-Infarct Dementia Market Drivers in Global Market

Table 3. Multi-Infarct Dementia Market Restraints in Global Market

Table 4. Key Players of Multi-Infarct Dementia in Global Market

Table 5. Top Multi-Infarct Dementia Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Multi-Infarct Dementia Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Multi-Infarct Dementia Revenue Share by Companies, 2017-2022

Table 8. Global Companies Multi-Infarct Dementia Product Type

Table 9. List of Global Tier 1 Multi-Infarct Dementia Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Multi-Infarct Dementia Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Multi-Infarct Dementia Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Multi-Infarct Dementia Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Multi-Infarct Dementia Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Multi-Infarct Dementia Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Multi-Infarct Dementia Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Multi-Infarct Dementia Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Multi-Infarct Dementia Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Multi-Infarct Dementia Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Multi-Infarct Dementia Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Multi-Infarct Dementia Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Multi-Infarct Dementia Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Multi-Infarct Dementia Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Multi-Infarct Dementia Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Multi-Infarct Dementia Revenue, (US\$, Mn), 2023-2028

Table 30. Forest Laboratories Corporate Summary

Table 31. Forest Laboratories Multi-Infarct Dementia Product Offerings

Table 32. Forest Laboratories Multi-Infarct Dementia Revenue (US\$, Mn), (2017-2022)

Table 33. Janssen Pharmaceuticals Corporate Summary

Table 34. Janssen Pharmaceuticals Multi-Infarct Dementia Product Offerings

Table 35. Janssen Pharmaceuticals Multi-Infarct Dementia Revenue (US\$, Mn), (2017-2022)

Table 36. Novartis Pharmaceutical Corporate Summary

Table 37. Novartis Pharmaceutical Multi-Infarct Dementia Product Offerings

Table 38. Novartis Pharmaceutical Multi-Infarct Dementia Revenue (US\$, Mn), (2017-2022)

Table 39. Pfizer Corporate Summary

Table 40. Pfizer Multi-Infarct Dementia Product Offerings

Table 41. Pfizer Multi-Infarct Dementia Revenue (US\$, Mn), (2017-2022)

Table 42. Eisai Corporate Summary

Table 43. Eisai Multi-Infarct Dementia Product Offerings

Table 44. Eisai Multi-Infarct Dementia Revenue (US\$, Mn), (2017-2022)

Table 45. Ortho-McNeil Pharmaceutical Corporate Summary

Table 46. Ortho-McNeil Pharmaceutical Multi-Infarct Dementia Product Offerings

Table 47. Ortho-McNeil Pharmaceutical Multi-Infarct Dementia Revenue (US\$, Mn), (2017-2022)

Table 48. Takeda Corporate Summary

Table 49. Takeda Multi-Infarct Dementia Product Offerings

Table 50. Takeda Multi-Infarct Dementia Revenue (US\$, Mn), (2017-2022)

Table 51. Jubilant Cadista Pharmaceuticals Corporate Summary

Table 52. Jubilant Cadista Pharmaceuticals Multi-Infarct Dementia Product Offerings

Table 53. Jubilant Cadista Pharmaceuticals Multi-Infarct Dementia Revenue (US\$, Mn), (2017-2022)

Table 54. Takeda Pharmaceutical Corporate Summary

Table 55. Takeda Pharmaceutical Multi-Infarct Dementia Product Offerings

Table 56. Takeda Pharmaceutical Multi-Infarct Dementia Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Multi-Infarct Dementia Segment by Type in 2021
- Figure 2. Multi-Infarct Dementia Segment by Application in 2021
- Figure 3. Global Multi-Infarct Dementia Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Multi-Infarct Dementia Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Multi-Infarct Dementia Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Multi-Infarct Dementia Revenue in 2021
- Figure 8. By Type - Global Multi-Infarct Dementia Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Multi-Infarct Dementia Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Multi-Infarct Dementia Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Multi-Infarct Dementia Revenue Market Share, 2017-2028
- Figure 12. US Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Multi-Infarct Dementia Revenue Market Share, 2017-2028
- Figure 16. Germany Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Multi-Infarct Dementia Revenue Market Share, 2017-2028
- Figure 24. China Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 28. India Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028
- Figure 29. By Country - South America Multi-Infarct Dementia Revenue Market Share, 2017-2028

Figure 30. Brazil Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Multi-Infarct Dementia Revenue Market Share, 2017-2028

Figure 33. Turkey Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Multi-Infarct Dementia Revenue, (US\$, Mn), 2017-2028

Figure 37. Forest Laboratories Multi-Infarct Dementia Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Janssen Pharmaceuticals Multi-Infarct Dementia Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Novartis Pharmaceutical Multi-Infarct Dementia Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Pfizer Multi-Infarct Dementia Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Eisai Multi-Infarct Dementia Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Ortho-McNeil Pharmaceutical Multi-Infarct Dementia Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Takeda Multi-Infarct Dementia Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Jubilant Cadista Pharmaceuticals Multi-Infarct Dementia Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Takeda Pharmaceutical Multi-Infarct Dementia Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Multi-Infarct Dementia Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/MAFA470C2838EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MAFA470C2838EN.html>